OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).
Stem Cell Therapy
Submission Deadline: December 30, 2018 (Open) Submit Now
Luis Martinez, MD
President and CEO, Regenera Global, San Juan, 00926, Puerto Rico
Research Interests: stem cell; cancer; regenerative medicine and cell therapy; preventive medicine; clinical research
About This Topic
The field of stem cell medicine is advancing at a rapid pace. Interestingly, this advancement has been, to a point, fueled by parallel pathways. On one end, point of care stem cell treatments offered in clinics, and under generally lax regulatory guidelines have served to provide much empirical data on the safety and possible applications of autologous stem cell treatments. On the other end, academic institutions, alongside pharmaceutical and biotech companies, have focused on studying the complex stem cell environment. The intention being the development of stem cell biological drugs that abide by the traditional regulatory channels and which utilize placebo controlled studies to demonstrate efficacy. Independently, these pathways are, more and more, converging on a compromise between obtaining robust data, and facilitating the regulatory process. The point is to accelerate patient access to these novel therapies.
If we look at aging as a failure of stem cells, then chronic degenerative diseases arise from our bodies inability to maintain proper repair mechanisms at the cellular level. With this in mind, this special issue will focus on the translational and current clinical applications of stem cell therapies as they relate to treating, stopping, or reversing the aging process and its complications.
We invite articles that contemplate, but are not limited to the following topics:
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.